Imagion Biosystems phase I study results

Imagion Biosystems Limited (ASX: $IBX) has announced positive results from the IBI10103 phase I clinical trial, demonstrating the safety and clinical feasibility of MagSense HER2 Imaging Agent (MSH2IA) as an adjunct to MRI for assessing axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer.

Dr. Isaac Bright on IBI10103 Phase I Study Results

Dr. Isaac Bright, Managing Director and CEO of Imagion, presented the data at the international San Antonio Breast Cancer Symposium, stating, 'Patients with HER2 positive breast cancer need better staging options that are safe, reliable, comprehensive, and less invasive than today's standard of care.' He further added, 'We are encouraged by MSH2IA's potential to increase the accuracy of disease staging, and thus improve treatment decisions.'

Summary of Imagion Biosystems announcement

The IBI10103 phase I study demonstrated the safety and clinical feasibility of MagSense HER2 Imaging Agent in assessing axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer. The results showed that MSH2IA has the potential to increase the accuracy of disease staging, leading to improved treatment decisions. Imagion Biosystems continues to work towards its Investigational New Drug application for submission to the US FDA, and the company is encouraged by the feedback the results are attracting from prospective partners. Molecular MRI with MSH2IA may emerge as the new standard of care for accurately staging the disease in patients diagnosed with HER2+ breast cancer.